Home / Specialty Pharmacy (page 20)

Specialty Pharmacy

Study Finds Low Levels of Adherence & Persistence Remain Barriers to Reducing Costs of Diabetes Complications

PARSIPPANY, N.J.–(BUSINESS WIRE)–Despite improved diagnosis and advances in treatment options for individuals with Type 2 Diabetes, sub-optimal therapy adherence and persistence result in significant economic and societal burden as well as avoidable patient complications in six diverse healthcare systems around the world, according to a new report series issued today …

Read More »

FDA Approves Amgen’s Single Monthly Injection for a PCSK9 Inhibitor

THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 …

Read More »

Metformin as a Potential Treatment for a Rare Pediatric Disorder

Maple Syrup Urine Disease (MSUD) is a rare inherited metabolic disorder involving the dysfunction of an enzyme which breaks down three essential amino acids: leucine, isoleucine and valine. Left untreated, infants die from a toxic buildup of resulting keto-acids within weeks of birth. Those who are diagnosed early can live …

Read More »

E-Consults Increase Access to Specialty Care, Reduce Need for Face-to-Face Appointments

Boston (06/26/16) – According to research presented today at AcademyHealth’s Annual Research Meeting, use by physicians of electronic consultations (e-consults) increases access to specialists’ care for patients who often have the hardest time getting a specialist, including the uninsured, underinsured and those living in rural areas. E-consults leverage electronic health …

Read More »

Alzheimer’s Genetics Point to New Research Direction

A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease. Previous research has revolved around the idea that accumulation in the brain of a small, sticky protein fragment — amyloid beta — causes Alzheimer’s disease. …

Read More »

OptiMed Specialty Pharmacy Extends its Reach of Patient-Centered Care

Kalamazoo, Michigan – OptiMed Specialty Pharmacy, a privately-held specialty pharmacy headquartered in Kalamazoo, Michigan, announced today the acquisition of the Specialty Pharmacy Business line of Advanced Therapeutics, a leading health care company in California. OptiMed Specialty Pharmacy aims to help patients, providers and stakeholders navigate the intricacies of specialty medication …

Read More »

Premier Acquires Lincare Holdings’ Specialty Pharmacy Business

CHARLOTTE, N.C.–(BUSINESS WIRE)–Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, has agreed to acquire the national specialty pharmacy business of Lincare Holdings Inc., headquartered in Clearwater, Fla. The $75 million acquisition includes Acro Pharmaceutical Services LLC and Community Pharmacy Services, LLC. Premier expects to fund the transaction with available …

Read More »

CVS Study Shows that Home Infusion Care Improves Patient Outcomes and QOL While Reducing Costs

WOONSOCKET, R.I., May 4, 2016 /PRNewswire/ — A new study by the CVS Health Research Institute found that home infusion care is safe, clinically effective and improves quality of life while reducing health care costs when compared to infusion care delivered in a hospital or clinic. The findings underscore the …

Read More »

FDA Approves Oral Suspension Formulation of Eisai’s Fycompa

WOODCLIFF LAKE, N.J., May 2, 2016 /PRNewswire/ — Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII Oral Suspension as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in …

Read More »

FDA Approves Acadia’s Nuplazid for Parkinson’s-Related Psychosis

The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease. Hallucinations or delusions can occur in as many as 50 percent of patients with Parkinson’s disease at some time during …

Read More »